Endocrinological derangements in COPD

European Respiratory Journal

Volumn 34, Issue 4, 2009, Pages 975-996

  Laghi, F ^a   Adiguzel, N ^a   Tobin, M J ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

Aldosterone; Diaphragm contractility; Insulin like growth factor I; Oestrogens; Testosterone; Thyroid

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CYTOKINE; GLUCOCORTICOID; INTERLEUKIN 1; INTERLEUKIN 6; PREDNISOLONE; SOMATOMEDIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ADRENAL DISEASE; BREATHING MECHANICS; BREATHING MUSCLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CORTICOSTEROID THERAPY; DEPRESSION; DIABETES MELLITUS; ENDOCRINE DISEASE; ENDOCRINE FUNCTION; ENZYME GLYCOSYLATION; EXERCISE; FLUID BALANCE; GAS EXCHANGE; GONAD DYSFUNCTION; HEART DISEASE; HEART FUNCTION; HUMAN; HYPERCAPNIA; HYPOGONADISM; HYPOPHYSIS DISEASE; HYPOXEMIA; INFLAMMATION; MALNUTRITION; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE WEAKNESS; NONHUMAN; OBESITY; OSTEOPOROSIS; OXIDATIVE STRESS; OXYGEN CONSUMPTION; PANCREAS DISEASE; PHYSICIAN; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PROTEIN SYNTHESIS; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESPIRATION CONTROL; RESPIRATORY DRIVE; REVIEW; SEXUAL FUNCTION; SMOKING; THYROID DISEASE;

ENDOCRINE SYSTEM DISEASES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 70349635557     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00103708     Document Type: Review

References (282)

1. Engelen MP, Schols AM, Baken WC, et al. Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7: 1793-1797.
2. Laaban JP, Kouchakji B, Dore MF, et al. Nutritional status of patients with chronic obstructive pulmonary disease and acute respiratory failure. Chest 1993; 103: 1362-1368. (Pubitemid 23145585)
3. Schols AM, Soeters PB, Mostert R, et al. Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit Care Med 1995; 152: 1268-1274.
4. Creutzberg EC, Casaburi R. Endocrinological disturbances in chronic obstructive pulmonary disease. Eur Respir J 2003; 22: Suppl. 46, 76s-80s. (Pubitemid 37351739)
5. Wagner PD. Skeletal muscles in chronic obstructive pulmonary disease: deconditioning, or myopathy? Respirology 2006; 11: 681-686. (Pubitemid 44581430)
6. Philippou A, Maridaki M, Halapas A, et al. The role of the insulin-like growth factor 1 (IGF-1) in skeletal muscle physiology. In Vivo 2007; 21: 45-54. (Pubitemid 46359198)
7. Maggio M, Lauretani F, Ceda GP, et al. Relationship between low levels of anabolic hormones and 6-year mortality in older men: the aging in the Chianti Area (InCHIANTI) study. Arch Intern Med 2007; 167: 2249-2254. (Pubitemid 350106746)
8. Bolster DR, Jefferson LS, Kimball SR. Regulation of protein synthesis associated with skeletal muscle hypertrophy by insulin-, amino acid- and exercise-induced signalling. Proc Nutr Soc 2004; 63: 351-356.
9. Yakar S, Liu JL, Stannard B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. Proc Natl Acad Sci USA 1999; 96: 7324-7329 (Pubitemid 29299660)
10. Crul T, Spruit MA, Gayan-Ramirez G, et al. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 2007; 37: 897-904. (Pubitemid 350029204)
11. Gayan-Ramirez G, Vanderhoydonc F, Verhoeven G, et al. Acute treatment with corticosteroids decreases IGF-1 and IGF-2 expression in the rat diaphragm and gastrocnemius. Am J Respir Crit Care Med 1999; 159: 283-289. (Pubitemid 29036536)
12. Pavelic J, Matijevic T, Knezevic J. Biological & physiological aspects of action of insulin-like growth factor peptide family. Indian J Med Res 2007; 125: 511-522. (Pubitemid 47099107)
13. Watson RT, Saltiel JE, Pessin JE, et al. Subcellular compartmentalization of insulin signaling processes and GLUT4 trafficking events. In: Saltiel AR, Pessin JE. Mechanisms of insulin action, 1st Edn. New York, Springer Science, 2007; pp. 33-51.
14. Doucet M, Russell AP, Leger B, et al. Muscle atrophy and hypertrophy signaling in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 261-269. (Pubitemid 47195876)
15. Laghi F, Tobin MJ. Disorders of the respiratory muscles. Am J Respir Crit Care Med 2003; 168: 10-48.
16. Sacheck JM, Ohtsuka A, McLary SC, et al. IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1. Am J Physiol Endocrinol Metab 2004; 287: E591-E601. (Pubitemid 39242684)
17. Singleton JR, Baker BL, Thorburn A. Dexamethasone inhibits insulin-like growth factor signaling and potentiates myoblast apoptosis. Endocrinology 2000; 141: 2945-2950. (Pubitemid 32250459)
18. Scalvini S, Volterrani M, Vitacca M, et al. Plasma hormone levels and haemodynamics in patients with chronic obstructive lung disease. Monaldi Arch Chest Dis 1996; 51: 380-386. (Pubitemid 27062781)
19. Leach RM, Forsling ML. The effect of changes in arterial PCO2 on neuroendocrine function in man. Exp Physiol 2004; 89: 287-292.
20. Marcell TJ. Sarcopenia: causes, consequences, and preventions. J Gerontol A Biol Sci Med Sci 2003; 58: M911-M916.
21. Marcell TJ, Harman SM, Urban RJ, et al. Comparison of GH, IGF-I, and testosterone with mRNA of receptors and myostatin in skeletal muscle in older men. Am J Physiol Endocrinol Metab 2001; 281: E1159-E1164. (Pubitemid 33775058)
22. Frutos MG, Cacicedo L, Fernandez C, et al. Insights into a role of GH secretagogues in reversing the age-related decline in the GH/IGF-I axis. Am J Physiol Endocrinol Metab 2007; 293: E1140-E1152. (Pubitemid 350106579)
23. Leifke E, Gorenoi V, Wichers C, et al. Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data froma healthy male cohort. Clin Endocrinol (Oxf) 2000; 53: 689-695. (Pubitemid 32096679)
24. Spencer JB, Klein M, Kumar A, et al. The age-associated decline of androgens in reproductive age and menopausal Black and White women. J Clin Endocrinol Metab 2007; 92: 4730-4733. (Pubitemid 350223451)
25. Awede B, Thissen J, Gailly P, et al. Regulation of IGF-I, IGFBP-4 and IGFBP-5 gene expression by loading in mouse skeletal muscle. FEBS Lett 1999; 461: 263-267.
26. Nindl BC, Alemany JA, Kellogg MD, et al. Utility of circulating IGF-I as a biomarker for assessing body composition changes in men during periods of high physical activity superimposed upon energy and sleep restriction. J Appl Physiol 2007; 103: 340-346.
27. Donahue SP, Phillips LS. Response of IGF-1 to nutritional support in malnourished hospital patients: a possible indicator of short-term changes in nutritional status. Am J Clin Nutr 1989; 50: 962-969.
28. Decramer M, Lacquet LM, Fagard R, et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994; 150: 11-16. (Pubitemid 24209929)
29. Saudny-Unterberger H, Martin JG, Gray-Donald K. Impact of nutritional support on functional status during an acute exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997; 156: 794-799. (Pubitemid 27396417)
30. Solomon AM, Bouloux PM. Modifying muscle mass - the endocrine perspective. J Endocrinol 2006; 191: 349-360.
31. Kritsch KR, Murali S, Adamo ML, et al. Dexamethasone decreases serum and liver IGF-I and maintains liver IGF-I mRNA in parenterally fed rats. Am J Physiol Regul Integr Comp Physiol 2002; 282: R528-R536. (Pubitemid 34664604)
32. Fournier M, Huang ZS, Li H, et al. Insulin-like growth factor I prevents corticosteroid-induced diaphragm muscle atrophy in emphysematous hamsters. Am J Physiol Regul Integr Comp Physiol 2003; 285: R34-R43. (Pubitemid 36736499)
33. Horber FF, Haymond MW. Human growth hormone prevents the protein catabolic side effects of prednisone in humans. J Clin Invest 1990; 86: 265-272.
34. Matsushita T, Kanda F, Sugio T, et al. [Growth hormone prevents the steroid myopathy in rats.]. Rinsho Shinkeigaku 1996; 36: 752-756.
35. Petrof BJ, Gottfried SB, Eby J, et al. Growth hormone does not prevent corticosteroid-induced changes in rat diaphragm structure and function. J Appl Physiol 1995; 79: 1571-1577.
36. Kanda F, Takatani K, Okuda S, et al. Preventive effects of insulinlike growth factor-I on steroid-induced muscle atrophy. Muscle Nerve 1999; 22: 213-217. (Pubitemid 29070395)
37. Morrison WL, Gibson JN, Scrimgeour C, et al. Muscle wasting in emphysema. Clin Sci (Lond) 1988; 75: 415-420.
38. Benso A, Broglio F, Aimaretti G, et al. Endocrine and metabolic responses to extreme altitude and physical exercise in climbers. Eur J Endocrinol 2007; 157: 733-740.
39. Dundar B, Akcoral A, Saylam G, et al. Chronic hypoxaemia leads to reduced serum IGF-I levels in cyanotic congenital heart disease. J Pediatr Endocrinol Metab 2000; 13: 431-436. (Pubitemid 30202260)
40. Iioka Y, Tatsumi K, Sugito K, et al. Effects of insulin-like growth factor on nitrogen balance during hypoxic exposure. Eur Respir J 2002; 20: 293-299. (Pubitemid 34905782)
41. Anand IS, Chandrashekhar Y, Ferrari R, et al. Pathogenesis of congestive state in chronic obstructive pulmonary disease. Studies of body water and sodium, renal function, hemodynamics, and plasma hormones during edema and after recovery. Circulation 1992; 86: 12-21.
42. Wouters EF. Local and systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005; 2: 26-33. (Pubitemid 40562960)
43. Broussard SR, McCusker RH, Novakofski JE, et al. Cytokine-hormone interactions: tumor necrosis factor alpha impairs biologic activity and downstream activation signals of the insulin-like growth factor I receptor in myoblasts. Endocrinology 2003; 144: 2988-2996.
44. Casaburi R, Goren S, Bhasin S. Substantial prevalence of low anabolic hormone levels in COPD patients undergoing rehabilitation. Am J Respir Crit Care Med 1996; 153: A128.
45. Casaburi R, Bhasin S, Cosentino L, et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 870-878. (Pubitemid 39346482)
46. Itoh T, Nagaya N, Yoshikawa M, et al. Elevated plasma ghrelin level in underweight patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170: 879-882. (Pubitemid 39346483)
47. Spruit MA, Gosselink R, Troosters T, et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003; 58: 752-756. (Pubitemid 37094049)
48. Burdet L, de Muralt B, Schutz Y, et al. Administration of growth hormone to underweight patients with chronic obstructive pulmonary disease. A prospective, randomized, controlled study. Am J Respir Crit Care Med 1997; 156: 1800-1806. (Pubitemid 28011785)
49. Debigare R, Marquis K, Cote CH, et al. Catabolic/anabolic balance and muscle wasting in patients with COPD. Chest 2003; 124: 83-89. (Pubitemid 36851335)
50. Koehler F, Doehner W, Hoernig S, et al. Anorexia in chronic obstructive pulmonary disease - association to cachexia and hormonal derangement. Int J Cardiol 2007; 119: 83-89. (Pubitemid 46818476)
51. Lewis MI, Fournier M, Da X, et al. Short-term influences of lung volume reduction surgery on the diaphragm in emphysematous hamsters. Am J Respir Crit Care Med 2004; 170: 753-759.
52. Pape GS, Friedman M, Underwood LE, et al. The effect of growth hormone on weight gain and pulmonary function in patients with chronic obstructive lung disease. Chest 1991; 99: 1495-1500.
53. Pichard C, Kyle U, Chevrolet JC, et al. Lack of effects of recombinant growth hormone on muscle function in patients requiring prolonged mechanical ventilation: a prospective, randomized, controlled study. Crit Care Med 1996; 24: 403-413. (Pubitemid 26097832)
54. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med 1999; 341: 785-792. (Pubitemid 29420473)
55. Schibler A, von der HR, Birrer P, et al. Prospective randomised treatment with recombinant human growth hormone in cystic fibrosis. Arch Dis Child 2003; 88: 1078-1081. (Pubitemid 38064483)
56. Schnabel D, Grasemann C, Staab D, et al. A multicenter, randomized, double-blind, placebo-controlled trial to evaluate the metabolic and respiratory effects of growth hormone in children with cystic fibrosis. Pediatrics 2007; 119: e1230-e1238. (Pubitemid 46871239)
57. Chahal HS, Drake WM. The endocrine system and ageing. J Pathol 2007; 211: 173-180.
58. Papadakis MA, Grady D, Black D, et al. Growth hormone replacement in healthy older men improves body composition but not functional ability. Ann Intern Med 1996; 124: 708-716. (Pubitemid 26117919)
59. Tentori L, Graziani G. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: is there a cancer risk? Pharmacol Res 2007; 55: 359-369.
60. Nagaya N, Itoh T, Murakami S, et al. Treatment of cachexia with ghrelin in patients with COPD. Chest 2005; 128: 1187-1193. (Pubitemid 41324394)
61. Vogiatzis I, Stratakos G, Simoes DC, et al. Effects of rehabilitative exercise on peripheral muscle TNFalpha, IL-6, IGF-I and MyoD expression in patients with COPD. Thorax 2007; 62: 950-956. (Pubitemid 350084492)
62. Rabinovich RA, Figueras M, Ardite E, et al. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J 2003; 21: 789-794. (Pubitemid 36592286)
63. Griffin JE, Ojeda SR. Textbook of Endocrine Physiology, 5 ed. New York, Oxford University Press, 2004.
64. Shifren JL, Braunstein GD, Simon JA, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. N Engl J Med 2000; 343: 682-688.
65. Watanobe H, Hayakawa Y. Hypothalamic interleukin-1 beta and tumor necrosis factor-alpha, but not interleukin-6, mediate the endotoxin-induced suppression of the reproductive axis in rats. Endocrinology 2003; 144: 4868-4875. (Pubitemid 37378401)
66. Griffin JE. Male Reproductive function. In: Griffin JE, Ojeda SR. Textbook of Endocrine Physiology. 5th Edn. New York, Oxford University Press, 2004; pp. 226-248.
67. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-492. (Pubitemid 38133769)
68. Lewis MI, Fournier M, Storer TW, et al. Skeletal muscle adaptations to testosterone and resistance training in men with COPD. J Appl Physiol 2007; 103: 1299-1310. (Pubitemid 47605967)
69. Herbst KL, Bhasin S. Testosterone action on skeletal muscle. Curr Opin Clin Nutr Metab Care 2004; 7: 271-277.
70. Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731.
71. Gray A, Feldman HA, McKinlay JB, et al. Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study. J Clin Endocrinol Metab 1991; 73: 1016-1025. (Pubitemid 21901140)
72. Haren MT, Banks WA, Perry Iii HM, et al. Predictors of serum testosterone and DHEAS in African-American men. Int J Androl 2008; 31: 50-59.
73. Snyder PJ. Hypogonadism in elderly men - what to do until the evidence comes. N Engl J Med 2004; 350: 440-442. (Pubitemid 38133763)
74. Biskobing DM. COPD and osteoporosis. Chest 2002; 121: 609-620.
75. Marquis K, Debigare R, Lacasse Y, et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 809-813.
76. Laghi F, Antonescu-Turcu A, Collins E, et al. Hypogonadism in men with chronic obstructive pulmonary disease: prevalence and quality of life. Am J Respir Crit Care Med 2005; 171: 728-733. (Pubitemid 40471143)
77. Kamischke A, Kemper DE, Castel MA, Luthke M, Rolf C, Behre HM, et al. Testosterone levels in men with chronic obstructive pulmonary disease with or without glucocorticoid therapy. Eur Respir J 1998; 11: 41-45. (Pubitemid 28081793)
78. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1105-1111. (Pubitemid 43066645)
79. Morley JE, Perry HM III. Androgen treatment of male hypogonadism in older males. J Steroid Biochem Mol Biol 2003; 85: 367-373.
80. Davison SL, Bell R, Donath S, et al. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90: 3847-3853. (Pubitemid 41058142)
81. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985; 60: 174-177.
82. Isidori AM, Lenzi A. Risk factors for androgen decline in older males: lifestyle, chronic diseases and drugs. J Endocrinol Invest 2005; 28: 14-22.
83. Karadag F, Ozcan H, Karul AB, et al. Sex hormone alterations and systemic inflammation in chronic obstructive pulmonary disease. Int J Clin Pract 2007; 63: 275-281.
84. Nierman DM, Mechanick JI. Hypotestosteronemia in chronically critically ill men. Crit Care Med 1999; 27: 2418-2421.
85. Semple PD, Beastall GH, Watson WS, et al. Serum testosterone depression associated with hypoxia in respiratory failure. Clin Sci (Lond) 1980; 58: 105-106. (Pubitemid 10062141)
86. English KM, Pugh PJ, Parry H, et al. Effect of cigarette smoking on levels of bioavailable testosterone in healthy men. Clin Sci (Lond) 2001; 100: 661-665. (Pubitemid 32523320)
87. Creutzberg EC, Schols AM. Anabolic steroids. Curr Opin Clin Nutr Metab Care 1999; 2: 243-253.
88. Mealy K, Robinson B, Millette CF, et al. The testicular effects of tumor necrosis factor. Ann Surg 1990; 211: 470-475. (Pubitemid 20138189)
89. van der PT, Romijn JA, Endert E, et al. Effects of tumor necrosis factor on the hypothalamic-pituitary-testicular axis in healthy men. Metabolism 1993; 42: 303-307. (Pubitemid 23073346)
90. Simpson ER, Clyne C, Rubin G, et al. Aromatase - a brief overview. Annu Rev Physiol 2002; 64: 93-127.
91. Cover PO, Baanah-Jones F, John CD, et al. Annexin 1 (lipocortin 1) mimics inhibitory effects of glucocorticoids on testosterone secretion and enhances effects of interleukin-1beta. Endocrine 2002; 18: 33-39. (Pubitemid 34828106)
92. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738. (Pubitemid 32113289)
93. Jockenhovel F, Blum WF, Vogel E, et al. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2510-2513. (Pubitemid 27337865)
94. Nystrom F, Ekman B, Osterlund M, et al. Serum leptin concentrations in a normal population and in GH deficiency: negative correlation with testosterone in men and effects of GH treatment. Clin Endocrinol (Oxf) 1997; 47: 191-198. (Pubitemid 27359899)
95. Broglio F, Gottero C, Benso A, et al. Effects of ghrelin on the insulin and glycemic responses to glucose, arginine, or free fatty acids load in humans. J Clin Endocrinol Metab 2003; 88: 4268-4272. (Pubitemid 37153730)
96. Nagaya N, Kojima M, Kangawa K. Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia. Intern Med 2006; 45: 127-134. (Pubitemid 43349437)
97. Cohen PG. Obesity in men: The hypogonadal-estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 2008; 70: 358-360.
98. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289. (Pubitemid 27172772)
99. Domingo-Salvany A, Lamarca R, Ferrer M, et al. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 680-685. (Pubitemid 34971850)
100. Oga T, Nishimura K, Tsukino M, et al. Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167: 544-549.
101. Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male 2007; 10: 139-153.
102. Osman IM, Godden DJ, Friend JA, et al. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 1997; 52: 67-71. (Pubitemid 27047228)
103. Barrett-Connor E, Von Muhlen DG, Kritz-Silverstein D. Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999; 84: 573-577. (Pubitemid 29075686)
104. Santoro N, Torrens J, Crawford S, et al. Correlates of circulating androgens in mid-life women: the study of women's health across the nation. J Clin Endocrinol Metab 2005; 90: 4836-4845. (Pubitemid 41159380)
105. Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Respir J 2008; 31: 667-677.
106. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145: 1321-1327.
107. Berwick DM, Murphy JM, Goldman PA, et al. Performance of a five-item mental health screening test. Med Care 1991; 29: 169-176.
108. Laghi F, Langbein WE, Antonescu-Turcu A, et al. Respiratory and skeletal muscles in hypogonadal men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171: 598-605. (Pubitemid 40365415)
109. Laghi F, Cattapan SE, Jubran A, et al. Is weaning failure caused by low-frequency fatigue of the diaphragm?Am J Respir Crit Care Med 2003; 167: 120-127.
110. Ferguson GT. Effects of cortisone and testosterone on diaphragmatic function and biochemistry in the rabbit. J Appl Physiol 1995; 78: 1459-1468.
111. Levine S, Kaiser L, Leferovich J, et al. Cellular adaptations in the diaphragm in chronic obstructive pulmonary disease. N Engl J Med 1997; 337: 1799-1806. (Pubitemid 28006784)
112. Bagatell CJ, Bremner WJ. Androgens in men - uses and abuses. N Engl J Med 1996; 334: 707-714.
113. Bhasin S, Bagatell CJ, Bremner WJ, et al. Issues in testosterone replacement in older men. J Clin Endocrinol.Metab 1998; 83: 3435-12448
114. Ferrando AA, Sheffield-Moore M, Yeckel CW, et al. Testosterone administration to older men improves muscle function: molecular and physiological mechanisms. Am J Physiol Endocrinol Metab 2002; 282: E601-E607. (Pubitemid 34654776)
115. Storer TW, Magliano L, Woodhouse L, et al. Testosterone dose-dependently increases maximal voluntary strength and leg power, but does not affect fatigability or specific tension. J Clin Endocrinol Metab 2003; 88: 1478-1485. (Pubitemid 36636978)
116. Snyder PJ, Peachey H, Hannoush P, et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: 2647-2653. (Pubitemid 30641987)
117. Wittert GA, Chapman IM, Haren MT, et al. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J Gerontol A Biol Sci Med Sci 2003; 58: 618-625.
118. Snyder PJ, Peachey H, Berlin JA, et al. Effects of testosterone replacement in hypogonadal men. J Clin Endocrinol Metab 2000; 85: 2670-2677. (Pubitemid 32269134)
119. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90: 678-688. (Pubitemid 40279179)
120. Casaburi R, Love RD, Bhasin S, et al. A randomized trial of testosterone supplementation in women with COPD. Am J Respir Crit Care Med 2007; 175: A851.
121. Ferreira IM, Verreschi IT, Nery LE, et al. The influence of 6 months of oral anabolic steroids on body mass and respiratory muscles in undernourished COPD patients. Chest 1998; 114: 19-28.
122. Creutzberg EC, Wouters EF, Mostert R, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003; 124: 1733-1742. (Pubitemid 37433566)
123. English KM, Mandour O, Steeds RP, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000; 21: 890-894. (Pubitemid 30307417)
124. Turhan S, Tulunay C, Gulec S, et al. The association between androgen levels and premature coronary artery disease in men. Coron Artery Dis 2007; 18: 159-162. (Pubitemid 46608491)
125. Rosano GM, Sheiban I, Massaro R, et al. Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res 2007; 19: 176-182. (Pubitemid 46340835)
126. Guthrie JR, Taffe JR, Lehert P, et al. Association between hormonal changes at menopause and the risk of a coronary event: a longitudinal study. Menopause 2004; 11: 315-322. (Pubitemid 40362186)
127. Young RP, Hopkins R, Eaton TE. Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes. Eur Respir J 2007; 30: 616-622. (Pubitemid 351194819)
128. Huiart L, Ernst P, Suissa S. Cardiovascular morbidity and mortality in COPD. Chest 2005; 128: 2640-2646
129. Sidney S, Sorel M, Quesenberry CP Jr, et al. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-2075. (Pubitemid 41507542)
130. Maclay JD, McAllister DA, Macnee W. Cardiovascular risk in chronic obstructive pulmonary disease. Respirology 2007; 12: 634-641. (Pubitemid 47414891)
131. Mannino DM, Thorn D, Swensen A, et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969.
132. Iqbal F, Michaelson J, Thaler L, et al. Declining bone mass in men with chronic pulmonary disease: contribution of glucocorticoid treatment, body mass index, and gonadal function. Chest 1999; 116: 1616-1624. (Pubitemid 30012703)
133. Thorevska N, Antonescu-Turcu A, Collins E, et al. Does hypogonadism in men with COPD affect sexual function, depression and bone mineral density? Am J Respir Crit Care Med 2005; 171: A64.
134. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men: a randomized controlled trial. JAMA 2008; 299: 39-52.
135. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Executive summary. In: Liverman CT, Blazer DG. Testosterone and aging: clinical research directions. Washington, DC, National Academy Press, 2004; pp. 1-10.
136. Tsuji K, Furutama D, Tagami M, et al. Specific binding and effects of dehydroepiandrosterone sulfate (DHEA-S) on skeletal muscle cells: possible implication for DHEA-S replacement therapy in patients with myotonic dystrophy. Life Sci 1999; 65: 17-26. (Pubitemid 29292801)
137. Morales AJ, Haubrich RH, Hwang JY, et al. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin Endocrinol (Oxf) 1998; 49: 421-432.
138. Christiansen JJ, Djurhuus CB, Gravholt CH, et al. Effects of cortisol on carbohydrate, lipid, and protein metabolism: studies of acute cortisol withdrawal in adrenocortical failure. J Clin Endocrinol Metab 2007; 92: 3553-3559.
139. Haren MT, Malmstrom TK, Banks WA, et al. Lower serum DHEAS levels are associated with a higher degree of physical disability and depressive symptoms in middle-aged to older African American women. Maturitas 2007; 57: 347-360.
140. Clark KD, Wardrobe-Wong N, Snashall PD. Endogenous cortisol and lung damage in a predominantly smoking population. Am J Respir Crit Care Med 1999; 159: 755-759. (Pubitemid 29137770)
141. Semple PD, Beastall GH, Watson WS, et al. Hypothalamic-pituitary dysfunction in respiratory hypoxia. Thorax 1981; 36: 605-609.
142. Gimenez M, Mohan-Kumar T, Humbert JC, et al. Haematological and hormonal responses to dynamic exercise in patients with chronic airway obstruction. Eur J Clin Invest 1987; 17: 75-80. (Pubitemid 17020049)
143. Mortimer KJ, Tata LJ, Smith CJ, et al. Oral and inhaled corticosteroids and adrenal insufficiency: a case-control study. Thorax 2006; 61: 405-408.
144. Cornil A, Glinoer D, Leclerco R, et al. Adrenocortical and somatotrophic secretions in acute and chronic respiratory insufficiency. Am Rev Respir Dis 1975; 112: 77-81.
145. Schuetz P, Christ-Crain M, Schild U, et al. Effect of a 14-day course of systemic corticosteroids on the hypothalamic-pituitary-adrenal-axis in patients with acute exacerbation of chronic obstructive pulmonary disease. BMC Pulm Med 2008; 8: 1. (Pubitemid 351285303)
146. Henzen C, Suter A, Lerch E, et al. Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment. Lancet 2000; 355: 542-545. (Pubitemid 30088675)
147. Nair KS, Rizza RA, O'Brien P, et al. DHEA in elderly women and DHEA or testosterone in elderly men. N Engl J Med 2006; 355: 1647-1659. (Pubitemid 44583955)
148. De Meyts P, Palsgaard J, Jensen AM, et al., Insulin and IGF-I Receptor Structure and Binding Mechanism. In: Saltiel AR, Pessin JE. Mechanisms of Insulin Action, 1 ed. New York: Springer Science, 2007; pp. 1-32.
149. Hsia CC, Raskin P. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med 2005; 118: 205-211. (Pubitemid 40312627)
150. Kahn CR, Saltiel AR. The Molecular Mechanism of Insulin Action and the Regulation of Glucose and Lipid Metabolism. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin's Diabetes Mellitus, 14 ed. Philadelphia: Lippincott Williams and Wilkins, 2005; pp. 145-168.
151. Bennett PH, Knowler WC. Definition, Diagnosis, and Classification of Diabetes Mellitus and Glucose Homeostasis. In: Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ. Joslin's Diabetes Mellitus, 14 ed. Philadelphia: Lippincott Williams and Wilkins, 2005; pp. 331-340.
152. Antonelli-Incalzi C, Imperiale C, Bellia V, et al. Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J 2003; 22: 444-449.
153. Watz H, Waschki B, Boehme C, et al. Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity. Am J Respir Crit Care Med 2007; 177: 743-751.
154. Walter RE, Beiser A, Givelber RJ, et al. Association between glycemic state and lung function: the Framingham Heart Study. Am J Respir Crit Care Med 2003; 167: 911-916. (Pubitemid 36801781)
155. Ford ES, Mannino DM. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care 2004; 27: 2966-2970.
156. Rana JS, Mittleman MA, Sheikh J, et al. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 2004; 27: 2478-2484. (Pubitemid 39281404)
157. Rimm EB, Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, et al. Cigarette smoking and the risk of diabetes in women. Am J Public Health 1993; 83: 211-214. (Pubitemid 23046478)
158. Rosen P, Nawroth PP, King G, et al. The role of oxidative stress in the onset and progression of diabetes and its complications: a summary of a Congress Series sponsored by UNESCO-MCBN, the American Diabetes Association and the German Diabetes Society. Diabetes Metab Res Rev 2001; 17: 189-212. (Pubitemid 32624602)
159. Barnes PJ. Chronic obstructive pulmonary disease. N Engl J Med 2000; 343: 269-280.
160. Bolton CE, Evans M, Ionescu AA, et al. Insulin resistance and inflammation - A further systemic complication of COPD. COPD 2007; 4: 121-126. (Pubitemid 47164861)
161. Blackburn D, Hux J, Mamdani M. Quantification of the Risk of Corticosteroid-induced Diabetes Mellitus Among the Elderly. J Gen Intern Med 2002; 17: 717-720. (Pubitemid 35013983)
162. Delaunay F, Khan A, Cintra A, et al. Pancreatic beta cells are important targets for the diabetogenic effects of glucocorticoids. J Clin Invest 1997; 100: 2094-2098. (Pubitemid 27459365)
163. Saad MJ, Folli F, Kahn JA, et al. Modulation of insulin receptor, insulin receptor substrate-1, and phosphatidylinositol 3-kinase in liver and muscle of dexamethasone-treated rats. J Clin Invest 1993; 92: 2065-2072. (Pubitemid 23304579)
164. Walters JA, Gibson PG, Wood-Baker R, et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; CD001288.
165. Baker EH, Janaway CH, Philips BJ, et al. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax 2006; 61: 284-289.
166. Gudmundsson G, Gislason T, Lindberg E, et al. Mortality in COPD patients discharged from hospital: the role of treatment and co-morbidity. Respir Res 2006; 7: 109. (Pubitemid 44355989)
167. Faul JL, Wilson SR, Chu JW, et al. The Effect of an Inhaled Corticosteroid on Glucose Control in Type 2 Diabetes. Clin Med Res 2009; 7: 14-20.
168. Wanke T, Formanek D, Auinger M, et al. Inspiratory muscle performance and pulmonary function changes in insulin-dependent diabetes mellitus. Am Rev Respir Dis 1991; 143: 97-100.
169. Wanke T, Paternostro-Sluga T, Grisold W, et al. Phrenic nerve function in type 1 diabetic patients with diaphragm weakness and peripheral neuropathy. Respiration 1992; 59: 233-237.
170. Ramamurthy B, Hook P, Jones AD, et al. Changes in myosin structure and function in response to glycation. FASEB J 2001; 15: 2415-2422. (Pubitemid 33063169)
171. Polotsky VY, Wilson JA, Haines AS, et al. The impact of insulin-dependent diabetes on ventilatory control in the mouse. Am J Respir Crit Care Med 2001; 163: 624-632. (Pubitemid 32230820)
172. Brannagan TH, Promisloff RA, McCluskey LF, et al. Proximal diabetic neuropathy presenting with respiratory weakness. J Neurol.Neurosurg.Psychiatry 1999; 67: 539-541. (Pubitemid 29438215)
173. White JE, Bullock RE, Hudgson P, et al. Phrenic neuropathy in association with diabetes. Diabet Med 1992; 9: 954-956.
174. Guazzi M, Brambilla R, De Vita S, et al. Diabetes worsens pulmonary diffusion in heart failure, and insulin counteracts this effect. Am J Respir Crit Care Med 2002; 166: 978-982. (Pubitemid 35193229)
175. Tantucci C, Bottini P, Fiorani C, et al. Cerebrovascular reactivity and hypercapnic respiratory drive in diabetic autonomic neuropathy. J Appl Physiol 2001; 90: 889-896. (Pubitemid 32171372)
176. Muller LM, Gorter KJ, Hak E, et al. Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 2005; 41: 281-288. (Pubitemid 41022101)
177. Moretti M, Cilione C, Tampieri A, et al. Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 2000; 55: 819-825. (Pubitemid 30744214)
178. Philips BJ, Meguer JX, Redman J, et al. Factors determining the appearance of glucose in upper and lower respiratory tract secretions. Intensive Care Med 2003; 29: 2204-2210. (Pubitemid 38030673)
179. Philips BJ, Redman J, Brennan A, et al. Glucose in bronchial aspirates increases the risk of respiratory MRSA in intubated patients. Thorax 2005; 60: 761-764. (Pubitemid 41297896)
180. Strotmeyer ES, Cauley JA, Schwartz AV, et al. Diabetes is associated independently of body composition with BMD and bone volume in older white and black men and women: The Health, Aging, and Body Composition Study. J Bone Miner Res 2004; 19: 1084-1091.
181. Hanley DA, Brown JP, Tenenhouse A, et al. Associations among disease conditions, bone mineral density, and prevalent vertebral deformities in men and women 50 years of age and older: cross-sectional results from the Canadian Multicentre Osteoporosis Study. J Bone Miner Res 2003; 18: 784-790. (Pubitemid 36899328)
182. Hofbauer LC, Brueck CC, Singh SK, et al. Osteoporosis in patients with diabetes mellitus. J Bone Miner Res 2007; 22: 1317-1328.
183. Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007; 13: Suppl. 1, 1-68.
184. McMahon GT, Arky RA. Inhaled insulin for diabetes mellitus. N Engl J Med 2007; 356: 497-502.
185. Standards of medical care in diabetes - 2008. Diabetes Care 2008; 31: Suppl. 1, S12-S54.
186. Burgers JS, Bailey JV, Klazinga NS, et al. Inside guidelines: comparative analysis of recommendations and evidence in diabetes guidelines from 13 countries. Diabetes Care 2002; 25: 1933-1939. (Pubitemid 41071047)
187. Siekmeier R, Scheuch G. Inhaled insulin - does it become reality? J Physiol Pharmacol 2008; 59: Suppl. 6, 81-113.
188. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; CD002967.
189. Yen PM. Genomic and nongenomic actions of thyroid hormones. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 135-150.
190. Silva JE. Intermediary metabolism and the sympathoadrenal system in hypothyroidism. In: Braverman LE, Utiger RD. The thyroid A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 817-823.
191. Klein I, Ojamaa K. Thyroid (neuro)myopathy. Lancet 2000; 356: 614.
192. Izumo S, Nadal-Ginard B, Mahdavi V. All members of the MHC multigene family respond to thyroid hormone in a highly tissue-specific manner. Science 1986; 231: 597-600. (Pubitemid 16088941)
193. Silva JE. Thermogenesis and sympathoadrenal system in thyrotoxicosis. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 607-620.
194. Saaresranta T, Polo O. Hormones and breathing. Chest 2002; 122: 2165-2182.
195. Karadag F, Ozcan H, Karul AB, et al. Correlates of non-thyroidal illness syndrome in chronic obstructive pulmonary disease. Respir Med 2007; 101: 1439-1446. (Pubitemid 46832231)
196. Dimopoulou I, Ilias I, Mastorakos G, et al. Effects of severity of chronic obstructive pulmonary disease on thyroid function. Metabolism 2001; 50: 1397-1401. (Pubitemid 34007407)
197. Wiersinga WM. Nonthyroidal illness. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 247-263.
198. Yu J, Koenig RJ. Induction of type 1 iodothyronine deiodinase to prevent the nonthyroidal illness syndrome in mice. Endocrinology 2006; 147: 3580-3585. (Pubitemid 43901150)
199. Bratel T, Wennlund A, Carlstrom K. Impact of hypoxaemia on neuroendocrine function and catecholamine secretion in chronic obstructive pulmonary disease (COPD). Effects of long-term oxygen treatment. Respir Med 2000; 94: 1221-1228.
200. Gow SM, Seth J, Beckett GJ, et al. Thyroid function and endocrine abnormalities in elderly patients with severe chronic obstructive lung disease. Thorax 1987; 42: 520-525. (Pubitemid 17097057)
201. Banks WA, Cooper JA. Hypoxia and hypercarbia of chronic lung disease: minimal effects on anterior pituitary function. South Med J 1990; 83: 290-293.
202. Wilber JF, Utiger RD. The effect of glucocorticoids on thyrotropin secretion. J Clin Invest 1969; 48: 2096-2103.
203. Nicoloff JT, Fisher DA, Appleman MD Jr. The role of glucocorticoids in the regulation of thyroid function in man. J Clin Invest 1970; 49: 1922-1929.
204. Rubello D, Sonino N, Casara D, et al. Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man. J Endocrinol Invest 1992; 15: 437-441.
205. Re RN, Kourides IA, Ridgway EC, et al. The effect of glucocorticoid administration on human pituitary secretion of thyrotropin and prolactin. J Clin Endocrinol Metab 1976; 43: 338-346.
206. LoPresti JS, Eigen A, Kaptein E, et al. Alterations in 3,3959-triiodothyronine metabolism in response to propylthiouracil, dexamethasone, and thyroxine administration in man. J Clin Invest 1989; 84: 1650-1656. (Pubitemid 19272255)
207. Chopra IJ, Williams DE, Orgiazzi J, et al. Opposite effects of dexamethasone on serum concentrations of 3,39,59-triiodothyronine (reverse T3) and 3,395-triiodothyronine (T3). J Clin Endocrinol Metab 1975; 41: 911-920.
208. Bergamaschi S, Rusconi R, Gervasoni M, et al. Pharmacokinetics of prednisone and prednisolone in a case of hypothyroidism: effect of replacement therapy. Steroids 2005; 70: 787-789. (Pubitemid 41169913)
209. Martinez FJ, Bermudez-Gomez M, Celli BR. Hypothyroidism. A reversible cause of diaphragmatic dysfunction. Chest 1989; 96: 1059-1063.
210. Siafakas NM, Salesiotou V, Filaditaki V, et al. Respiratory muscle strength in hypothyroidism. Chest 1992; 102: 189-194.
211. Laroche CM, Cairns T, Moxham J, et al. Hypothyroidism presenting with respiratory muscle weakness. Am Rev Respir Dis 1988; 138: 472-474. (Pubitemid 18201914)
212. Prakash YS, Gosselin LE, Zhan WZ, et al. Alterations of diaphragm neuromuscular junctions with hypothyroidism. J Appl Physiol 1996; 81: 1240-1248. (Pubitemid 26309133)
213. Datta D, Scalise P. Hypothyroidism and failure to wean in patients receiving prolonged mechanical ventilation at a regional weaning center. Chest 2004; 126: 1307-1312. (Pubitemid 39391265)
214. Pandya K, Lal C, Scheinhorn D, et al. Hypothyroidism and ventilator dependency. Arch Intern Med 1989; 149: 2115-2116.
215. Ladenson PW, Goldenheim PD, Ridgway EC. Prediction and reversal of blunted ventilatory responsiveness in patients with hypothyroidism. Am J Med 1988; 84: 877-883.
216. Wilson WR, Bedell GN. The pulmonary abnormalities in myxedema. J Clin Invest 1960; 39: 42-55.
217. Caraccio N, Natali A, Sironi A, et al. Muscle metabolism and exercise tolerance in subclinical hypothyroidism: a controlled trial of levothyroxine. J Clin Endocrinol Metab 2005; 90: 4057-4062. (Pubitemid 41058172)
218. Khaleeli AA, Griffith DG, Edwards RH. The clinical presentation of hypothyroid myopathy and its relationship to abnormalities in structure and function of skeletal muscle. Clin Endocrinol (Oxf) 1983; 19: 365-376.
219. Biondi B, Palmieri EA, Lombardi G, et al. Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 2002; 137: 904-914. (Pubitemid 35416626)
220. Rajagopal KR, Abbrecht PH, Derderian SS, et al. Obstructive sleep apnea in hypothyroidism. Ann Intern Med 1984; 101: 491-494.
221. Lin CC, Tsan KW, Chen PJ. The relationship between sleep apnea syndrome and hypothyroidism. Chest 1992; 102: 1663-1667. (Pubitemid 23001204)
222. Jha A, Sharma SK, Tandon N, et al. Thyroxine replacement therapy reverses sleep-disordered breathing in patients with primary hypothyroidism. Sleep Med 2006; 7: 55-61. (Pubitemid 43033546)
223. Pelttari L, Rauhala E, Polo O, et al. Upper airway obstruction in hypothyroidism. J Intern Med 1994; 236: 177-181.
224. Grunstein RR, Sullivan CE. Sleep apnea and hypothyroidism: mechanisms and management. Am J Med 1988; 85: 775-779.
225. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8: 457-469. (Pubitemid 35423133)
226. Bengel FM, Nekolla SG, Ibrahim T, et al. Effect of thyroid hormones on cardiac function, geometry, and oxidative metabolism assessed noninvasively by positron emission tomography and magnetic resonance imaging. J Clin Endocrinol Metab 2000; 85: 1822-1827. (Pubitemid 32269283)
227. Asvold BO, Bjoro T, Nilsen TI, et al. Tobacco smoking and thyroid function: a population-based study. Arch Intern Med 2007; 167: 1428-1432. (Pubitemid 47052443)
228. Okutan O, Kartaloglu Z, Onde ME, et al. Pulmonary function tests and thyroid hormone concentrations in patients with chronic obstructive pulmonary disease. Med Princ Pract 2004; 13: 126-128. (Pubitemid 38456641)
229. McElvaney GN, Wilcox PG, Fairbarn MS, et al. Respiratory muscle weakness and dyspnea in thyrotoxic patients. Am Rev Respir Dis 1990; 141: 1221-1227. (Pubitemid 20172575)
230. Mier A, Brophy C, Wass JA, et al. Reversible respiratory muscle weakness in hyperthyroidism. Am Rev Respir Dis 1989; 139: 529-533. (Pubitemid 19057436)
231. Pino-Garcia JM, Garcia-Rio F, Diez JJ, et al. Regulation of breathing in hyperthyroidism: relationship to hormonal and metabolic changes. Eur Respir J 1998; 12: 400-407. (Pubitemid 28389536)
232. Norrelund H, Hove KY, Brems-Dalgaard E, et al. Muscle mass and function in thyrotoxic patients before and during medical treatment. Clin Endocrinol (Oxf) 1999; 51: 693-699. (Pubitemid 30050818)
233. Stein M, Kimbel P, Johnson RL. Pulmonary function in hyperthyroidism. J Clin Invest 1961; 40: 348-363.
234. Tawa NE Jr, Odessey R, Goldberg AL. Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles. J Clin Invest 1997; 100: 197-203. (Pubitemid 27311258)
235. Miyashita A, Suzuki S, Suzuki M, et al. Effect of thyroid hormone on in vivo contractility of the canine diaphragm. Am Rev Respir Dis 1992; 145: 1452-1462.
236. Yamada T, Mishima T, Sakamoto M, et al. Myofibrillar protein oxidation and contractile dysfunction in hyperthyroid rat diaphragm. J Appl Physiol 2007; 102: 1850-1855. (Pubitemid 46701954)
237. Olson BR, Klein I, Benner R, et al. Hyperthyroid myopathy and the response to treatment. Thyroid 1991; 1: 137-141.
238. Duyff RF, Van den BJ, Laman DM, et al. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry 2000; 68: 750-755. (Pubitemid 30265276)
239. Freedman S. Lung volumes and distensibility, and maximum respiratory pressures in thyroid disease before and after treatment. Thorax 1978; 33: 785-790. (Pubitemid 9106437)
240. Massey DG, Becklake MR, McKenzie JM, et al. Circulatory and ventilatory response to exercise in thyrotoxicosis. N Engl J Med 1967; 276: 1104-1112.
241. Kahaly GJ, Nieswandt J, Wagner S, et al. Ineffective cardiorespiratory function in hyperthyroidism. J Clin Endocrinol Metab 1998; 83: 4075-4078.
242. Small D, Gibbons W, Levy RD, et al. Exertional dyspnea and ventilation in hyperthyroidism. Chest 1992; 101: 1268-1273.
243. Settipane GA, Schoenfeld E, Hamolsky MW. Asthma and hyperthyroidism. J Allergy Clin Immunol 1972; 49: 348-355.
244. White NW, Raine RI, Bateman ED. Asthma and hyperthyroidism. A report of 4 cases. S Afr Med J 1990; 78: 750-752.
245. Ayres J, Clark TJ. Asthma and the thyroid. Lancet 1981; 2: 1110-1111.
246. Ingbar DH. The pulmonary system in hypothyroidism. In: Braverman LE, Utiger RD. The thyroid. A fundamental and clinical text, 9 ed. Philadelphia, Lippincott Williams & Wilkins, 2005; pp. 781-788.
247. Kahaly GJ, Kampmann C, Mohr-Kahaly S. Cardiovascular hemodynamics and exercise tolerance in thyroid disease. Thyroid 2002; 12: 473-481. (Pubitemid 34721543)
248. Mercuro G, Panzuto MG, Bina A, et al. Cardiac function, physical exercise capacity, and quality of life during long-termthyrotropin-suppressive therapy with levothyroxine: effect of individual dose tailoring. J Clin Endocrinol Metab 2000; 85: 159-164. (Pubitemid 32268807)
249. Caiozzo VJ, Herrick RE, Baldwin KM. Influence of hyperthyroidism on maximal shortening velocity and myosin isoform distribution in skeletal muscles. Am J Physiol 1991; 261: C285-C295.
250. Sinclair C, Gilchrist JM, Hennessey JV, et al. Muscle carnitine in hypo- and hyperthyroidism. Muscle Nerve 2005; 32: 357-359.
251. Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med 2001; 344: 501-509.
252. de Leeuw PW, Dees A. Fluid homeostasis in chronic obstructive lung disease. Eur Respir J 2003; 22: Suppl. 46, 33s-40s. (Pubitemid 37351735)
253. Das BB, Solinger R. Role of natriuretic peptide family in cardiovascular medicine. Cardiovasc Hematol Agents Med Chem 2009; 7: 29-42.
254. Farber MO, Bright TP, Strawbridge RA, et al. Impaired water handling in chronic obstructive lung disease. J Lab Clin Med 1975; 85: 41-49.
255. Farber MO, Roberts LR, Weinberger MH, et al. Abnormalities of sodium and H2O handling in chronic obstructive lung disease. Arch Intern Med 1982; 142: 1326-1330. (Pubitemid 12087788)
256. Farber MO, Weinberger MH, Robertson GL, et al. Hormonal abnormalities affecting sodium and water balance in acute respiratory failure due to chronic obstructive lung disease. Chest 1984; 85: 49-54.
257. Stewart AG, Waterhouse JC, Billings CG, et al. Hormonal, renal, and autonomic nerve factors involved in the excretion of sodium and water during dynamic salt and water loading in hypoxaemic chronic obstructive pulmonary disease. Thorax 1995; 50: 838-845.
258. Renzetti AD Jr, McClement JH, Litt BD. The Veterans Administration cooperative study of pulmonary function. 3. Mortality in relation to respiratory function in chronic obstructive pulmonary disease. Am J Med 1966; 41: 115-129.
259. Weitzenblum E, Apprill M, Oswald M, et al. Pulmonary hemodynamics in patients with chronic obstructive pulmonary disease before and during an episode of peripheral edema. Chest 1994; 105: 1377-1382. (Pubitemid 24152591)
260. Wouters EF. Management of severe COPD. Lancet 2004; 364: 883-895.
261. Macnee W. Right ventricular function in cor pulmonale. Cardiology 1988; 75: Suppl. 1, 30-40. (Pubitemid 18248424)
262. Physiology of Respiration, 2 ed. Chicago: Year Book Medical Publishers, 1974.
263. Wendling MG, Eckstein JW, Abboud FM. Cardiovascular responses to carbon dioxide before and after β-adrenergic blockade. J Appl Physiol 1967; 22: 223-226.
264. Baudouin SV. Oedema and cor pulmonale revisited. Thorax 1997; 52: 401-402.
265. Baudouin SV, Bott J, Ward A, et al. Short term effect of oxygen on renal haemodynamics in patients with hypoxaemic chronic obstructive airways disease. Thorax 1992; 47: 550-554.
266. Howes TQ, Deane CR, Levin GE, et al. The effects of oxygen and dopamine on renal and aortic blood flow in chronic obstructive pulmonary disease with hypoxaemia and hypercapnia. Am J Respir Crit Care Med 1995; 151: 378-383.
267. Sharkey RA, Mulloy EM, O'Neill SJ. The acute effects of oxygen and carbon dioxide on renal vascular resistance in patients with an acute exacerbation of COPD. Chest 1999; 115: 1588-1592.
268. Laghi F, Tobin MJ. Indications for Mechanical Ventilation. In: Tobin MJ. Principles and Practice of Mechanical Ventilation. 2nd Edn. New York, Mc Graw Hill, 2006; pp. 129-162.
269. White RJ, Woodings DF. Impaired water handling in chronic obstructive airways disease. Br Med J 1971; 2: 561-563.
270. Skwarski K, Lee M, Turnbull L, et al. Atrial natriuretic peptide in stable and decompensated chronic obstructive pulmonary disease. Thorax 1993; 48: 730-735. (Pubitemid 23214867)
271. Stewart AG, Waterhouse JC, Billings CG, et al. Effects of angiotensin converting enzyme inhibition on sodium excretion in patients with hypoxaemic chronic obstructive pulmonary disease. Thorax 1994; 49: 995-998.
272. Chabot F, Mertes PM, Delorme N, et al. Effect of acute hypercapnia on alpha atrial natriuretic peptide, renin, angiotensin II, aldosterone, and vasopressin plasma levels in patients with COPD. Chest 1995; 107: 780-786.
273. Stewart AG, Waterhouse JC, Howard P. Cardiovascular autonomic nerve function in patients with hypoxaemic chronic obstructive pulmonary disease. Eur Respir J 1991; 4: 1207-1214.
274. Stewart AG, Marsh F, Waterhouse JC, et al. Autonomic nerve dysfunction in COPD as assessed by the acetylcholine sweat-spot test. Eur Respir J 1994; 7: 1090-1095. (Pubitemid 24187329)
275. Schrier RW, Berl T. Mechanism of the antidiuretic effect associated with interruption of parasympathetic pathways. J Clin Invest 1972; 51: 2613-2620.
276. Chhabra SK, De S. Cardiovascular autonomic neuropathy in chronic obstructive pulmonary disease. Respir Med 2005; 99: 126-133.
277. Chen WL, Chen GY, Kuo CD. Hypoxaemia and autonomic nervous dysfunction in patients with chronic obstructive pulmonary disease. Respir Med 2006; 100: 1547-1553. (Pubitemid 44089366)
278. Mannix ET, Dowdeswell I, Carlone S, et al. The effect of oxygen on sodium excretion in hypoxaemic patients with chronic obstructive lung disease. Chest 1990; 97: 840-844. (Pubitemid 20132305)
279. Farber MO, Weinberger MH, Robertson GL, et al. The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136: 862-866.
280. Valli G, Fedeli A, Antonucci R, et al. Water and sodium imbalance in COPD patients. Monaldi Arch Chest Dis 2004; 61: 112-116. (Pubitemid 39386842)
281. Brijker F, Heijdra YF, van den Elshout FJ, et al. Discontinuation of furosemide decreases PaCO(2) in patients with COPD. Chest 2002; 121: 377-382.
282. Farber MO, Weinberger MH, Robertson GL, et al. The effects of angiotensin-converting enzyme inhibition on sodium handling in patients with advanced chronic obstructive pulmonary disease. Am Rev Respir Dis 1987; 136: 862-866.